We Claim:

1. A compound of formula **1**



1

wherein:

R^1 is a group



,

wherein

R^3 is a benzyl group optionally substituted by a methoxy group,

R^4 is a hydrogen atom, or

R^3 and R^4 together are a -CO-CH_2-O- bridge, the carbonyl group of the bridge being bound to the nitrogen; and

R^2 is a group selected from



,

wherein

R^5 is a dimethylamino, methoxy, or butoxy group,

X is a nitrogen or a carbon atom, and

R^6 is a methoxyphenyl group, if X is nitrogen, or is an anellated phenyl ring also linked to X, if X is carbon,

or the individual optical isomers, mixtures of the individual enantiomers, racemates, or acid addition salt thereof.

2. The compound of formula **1** according to claim 1, wherein:

R^1 is a group selected from



; and

R^2 is a group selected from



3. The compound of formula **1** according to one of claim 1, wherein:

R^1 is a group selected from



; and

R^2 is a group selected from



4. The compound of formula **1** according to claim 1, wherein:

R^1 is a group



,

wherein R^3 and R^4 together are a -CO-CH_2-O- bridge, the carbonyl group of the bridge being bound to the nitrogen; and

R^2 is a group selected from



,

wherein

R^5 is a dimethylamino, methoxy, or butoxy group,

X is a nitrogen or a carbon atom, and

R^6 is a methoxyphenyl group, if X is nitrogen, or an anellated phenyl ring also linked to X, if X is carbon.

5. The compound of formula **1** according to claim 1, wherein:

R^1 is a group



; and

R^2 is a group selected from



6. The compound of formula **1** according to claim 1, wherein:

R^1 is a group



wherein

R^3 is a benzyl group optionally substituted by methoxy, and

R^4 is a hydrogen atom; and

R^2 is a group



wherein

X is a nitrogen or a carbon atom,

R^6 is a methoxyphenyl group, if X is nitrogen, or an anellated phenyl ring also linked to X, if X is carbon.

7. A compound of formula **1** according to one of claims 1 to 6, wherein the hydroxy group in the group R^1 is in the *ortho* or *meta* position to the amino group.

8. 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, or the individual optical isomers, mixtures of the individual enantiomers, racemates, or acid addition salt thereof.

9. 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*N*,*N*-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol, or the individual optical isomers, mixtures of the individual enantiomers, racemates, or acid addition salt thereof.

10. 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*n*-butyloxyphenyl)-2-methyl-2-propylamino]ethanol, or the individual optical isomers, mixtures of the individual enantiomers, racemates, or acid addition salt thereof.

11. The compound according to one of claims 1 to 10, wherein the acid addition salt thereof is formed with a pharmacologically acceptable acid.

12. A method of treating bronchial asthma, the inflammatory component in COPD, premature onset of labor in midwifery (tocolysis), atrio-ventricular block, bradycardiac hearth rhythm disorders, circulatory shock, or itching and inflammation of the skin in a host in need of such treatment, the method comprising administering to the host the compound according to one of claims 1 to 10.

13. A pharmaceutical preparation comprising a compound according to one of claims 1 to 11, optionally combined with conventional excipients and/or carriers.

14. The pharmaceutical preparation according to claim 13, further comprising at least one other active substance selected from the group consisting of anticholinergics, betamimetics, antiallergics, PAF antagonists, leukotriene antagonists, and steroids.

15. The pharmaceutical preparation according to claim 14, further comprising tiotropium bromide.